-
公开(公告)号：US20060276421A1
公开(公告)日：2006-12-07
申请号：US10568226
申请日：2004-09-29
CPC分类号： A61K31/713 , C12N15/111 , C12N2310/11 , C12N2310/14 , C12N2310/53 , C12N2320/51
摘要： Conventional oligonucleotides are opened at both ends and thereby unstable. The stability of them against catabolic enzymes is increased by phosphorothioate modification, but such phosphorothioate causes toxicity. The present invention provides oligonucleotides and medicaments in which these problems are improved. That is, it provides a staple oligonucleotides and medicaments containing the same as the active ingredient. Specifically, it provides transcription factor inhibitors, antisense oligonucleotides and siRNAs. More specifically, it provides agents for preventing, treating or improving inflammation, autoimmune diseases, central diseases, reperfusion injury in ischaemic diseases, worsened prognosis after organ transplantation or organ surgery, or restenosis after PTCA. Further specifically, it provides agents for preventing, treating or improving arthritis, dermatitis, nephritis, hepatitis, renal failure, cystitis, prostatitis, urethritis, ulcerative colitis, Crohn disease, chronic rheumatoid arthritis, osteoarthritis, atopic dermatitis, contact dermatitis, psoriasis, cutaneous ulcer or decubitus.
摘要翻译： 常规寡核苷酸在两端开放，从而不稳定。 它们对分解代谢酶的稳定性被硫代磷酸酯修饰增加，但是这种硫代磷酸酯引起毒性。 本发明提供了改善这些问题的寡核苷酸和药物。 也就是说，它提供了含有与活性成分相同的主要寡核苷酸和药物。 具体来说，它提供转录因子抑制剂，反义寡核苷酸和siRNA。 更具体地说，它提供用于预防，治疗或改善炎症，自身免疫性疾病，中枢性疾病，缺血性疾病中的再灌注损伤，器官移植或器官手术后的预后恶化或PTCA后的再狭窄的药剂。 更具体地说，它提供预防，治疗或改善关节炎，皮炎，肾炎，肝炎，肾衰竭，膀胱炎，前列腺炎，尿道炎，溃疡性结肠炎，克罗恩病，慢性类风湿性关节炎，骨关节炎，特应性皮炎，接触性皮炎，牛皮癣，皮肤 溃疡或褥疮。
-
公开(公告)号：US07595301B2
公开(公告)日：2009-09-29
申请号：US10568226
申请日：2004-09-29
CPC分类号： A61K31/713 , C12N15/111 , C12N2310/11 , C12N2310/14 , C12N2310/53 , C12N2320/51
摘要： Conventional oligonucleotides are opened at both ends and thereby unstable. Their stability against catabolic enzymes is increased by phosphorothioate modification, but such phosphorothioate causes toxicity. The present invention provides oligonucleotides and medicaments in which these problems are improved. That is, it provides staple oligonucleotides and medicaments containing the same as the active ingredient. Specifically, it provides transcription factor inhibitors, antisense oligonucleotides and siRNAs. More specifically, it provides agents for preventing, treating or improving inflammation, autoimmune diseases, central diseases, reperfusion injury in ischaemic diseases, worsened prognosis after organ transplantation or organ surgery, or restenosis after PTCA. Further specifically, it provides agents for preventing, treating or improving arthritis, dermatitis, nephritis, hepatitis, renal failure, cystitis, prostatitis, urethritis, ulcerative colitis, Crohn disease, chronic rheumatoid arthritis, osteoarthritis, atopic dermatitis, contact dermatitis, psoriasis, cutaneous ulcer or decubitus.
摘要翻译： 常规寡核苷酸在两端开放，从而不稳定。 它们对分解代谢酶的稳定性通过硫代磷酸酯修饰而增加，但是这种硫代磷酸酯会引起毒性。 本发明提供了改善这些问题的寡核苷酸和药物。 也就是说，它提供含有与活性成分相同的主要寡核苷酸和药物。 具体来说，它提供转录因子抑制剂，反义寡核苷酸和siRNA。 更具体地说，它提供用于预防，治疗或改善炎症，自身免疫性疾病，中枢性疾病，缺血性疾病中的再灌注损伤，器官移植或器官手术后的预后恶化或PTCA后的再狭窄的药剂。 更具体地说，它提供预防，治疗或改善关节炎，皮炎，肾炎，肝炎，肾衰竭，膀胱炎，前列腺炎，尿道炎，溃疡性结肠炎，克罗恩病，慢性类风湿性关节炎，骨关节炎，特应性皮炎，接触性皮炎，牛皮癣，皮肤 溃疡或褥疮。
-
公开(公告)号：US20070293447A1
公开(公告)日：2007-12-20
申请号：US10570052
申请日：2004-08-27
申请人： Yasuo Kunugiza , Naruya Tomita , Hideki Yoshikawa , Yoshiaki Taniyama , Katsuto Tamai , Ryuichi Morishita
发明人： Yasuo Kunugiza , Naruya Tomita , Hideki Yoshikawa , Yoshiaki Taniyama , Katsuto Tamai , Ryuichi Morishita
CPC分类号： A61K9/0024 , A61K31/7088 , A61K48/0075
摘要： The present invention provides highly useful clinical methods for treating skin disorders, particularly intractable skin disorders. Specifically, the methods comprise injecting/subcutaneously introducing a 10 μg to 10 mg dose of a polynucleotide, such as a DNA, oligonucleotide, RNA, siRNA, and antisense, around a lesion associated with a skin disorder, such as a wound, cutaneous ulcer, or psoriasis, using a needleless syringe that injects a pharmaceutical liquid by using gas pressure or the elastic force of an elastic member to drive a piston.
摘要翻译： 本发明提供用于治疗皮肤病症，特别是顽固性皮肤病症的非常有用的临床方法。 具体地说，所述方法包括将注射/皮下注射10μg至10mg剂量的多核苷酸，例如DNA，寡核苷酸，RNA，siRNA和反义，在与皮肤病症如伤口，皮肤溃疡相关的病变周围 或牛皮癣，使用无针注射器，其通过使用气体压力或弹性构件的弹力来驱动活塞而喷射药液。
-
公开(公告)号：US20070066935A1
公开(公告)日：2007-03-22
申请号：US10555925
申请日：2004-04-30
申请人： Ryuichi Morishita , Naruya Tomita , Yasuo Kunugiza , Yoshiaki Taniyama , Hiromi Koike , Haruhide Udagawa , Tatsuo Kimura
发明人： Ryuichi Morishita , Naruya Tomita , Yasuo Kunugiza , Yoshiaki Taniyama , Hiromi Koike , Haruhide Udagawa , Tatsuo Kimura
IPC分类号： A61M5/30
CPC分类号： A61M5/30 , A61K38/1833 , A61K48/00
摘要： The present invention provides a needleless syringe having, accommodated therein, a pharmaceutical preparation containing genes and/or analogues thereof. A needleless syringe comprising: a medical agent chamber 22 having one or multiple nozzle bore(s) 25 and accommodated with a medical agent L, and a syringe main body 12 being provided with pressure application means 32 to apply pressure on the medical agent L toward a direction of the nozzle bore(s) 25 and effect emission of the medical agent L through the nozzle bore(s) 25, wherein the medical agent L is a pharmaceutical preparation containing genes and/or analogues thereof. Examples of the medical agent L include pharmaceutical preparation containing HGF gene and pharmaceutical preparation containing NF-κB decoy oligonucleotide.
摘要翻译： 本发明提供一种无针注射器，其中容纳有含有其基因和/或类似物的药物制剂。 一种无针注射器，包括：药剂腔室22，其具有一个或多个喷嘴孔25并且容纳有药剂L;以及注射器主体12，其设有施加压力的压力施加装置32，以对药剂L施加压力 喷嘴孔25的方向并且通过喷嘴孔25发射药剂L，其中药剂L是含有其基因和/或类似物的药物制剂。 药剂L的实例包括含有HGF基因的药物制剂和含有NF-κB诱饵寡核苷酸的药物制剂。
-
5.发明申请Compositions inhibiting rejection in organ transplantation and method of using the same 审中-公开组织抑制器官移植排斥反应及其使用方法公开(公告)号：US20050175539A1
公开(公告)日：2005-08-11
申请号：US10496332
申请日：2002-11-20
CPC分类号： A61K49/223 , A61K31/7088
摘要： A novel and effective strategy for organ transplantation is provided. A therapeutic agent and method for preventing an acute rejection in a transplanted organ and improving prognosis are provided. A therapeutic agent for suppressing a rejection in organ transplantation, which comprises an NF-κB decoy compound, is provided. Representatively, the organ transplantation is kidney transplantation. The therapeutic agent further comprises an ultrasonic inspection contrast agent. A therapeutic agent for improving prognosis in organ transplantation is also provided. The therapeutic agent is administered into a donor organ. The transfection efficiency of the NF-κB decoy compound into the organ may be enhanced by ultrasound treatment.
摘要翻译： 提供了一种新颖有效的器官移植策略。 提供了用于预防移植器官中的急性排斥反应并改善预后的治疗剂和方法。 提供了一种用于抑制器官移植排斥反应的治疗剂，其包含NF-κB诱饵化合物。 代表性器官移植是肾移植。 治疗剂还包括超声波检查造影剂。 还提供了改善器官移植预后的治疗剂。 将治疗剂施用于供体器官。 通过超声处理可以增强NF-κB诱饵化合物进入器官的转染效率。
-
公开(公告)号：US20060241066A1
公开(公告)日：2006-10-26
申请号：US10516208
申请日：2003-05-20
CPC分类号： A61K31/7088 , A61K38/1709 , A61K48/005
摘要： It is intended to efficiently treat an inflammatory disease without causing side effects. This object can be achieved by providing a medicinal composition for treating and preventing an inflammatory disease and disorders, and disorders caused by the disease and disorders which contains at least one decoy of NF-κB or an analogous transcriptional factor and a pharmaceutically acceptable carrier; and a method of treating and preventing an inflammatory disease and disorders, and disorders caused by the disease and disorders which comprises the step of administering to a patient a composition containing at least one decoy of NF-κB or an analogous transcriptional factor and a pharmaceutically acceptable carrier.
摘要翻译： 旨在有效地治疗炎性疾病而不引起副作用。 该目的可以通过提供一种用于治疗和预防炎性疾病和病症的药物组合物，以及由包含至少一种NF-κB诱变物或类似转录因子和药学上可接受的载体的疾病和病症引起的疾病， 以及治疗和预防炎性疾病和病症以及由疾病和病症引起的疾病的方法，其包括向患者施用含有至少一种NF-κB诱变物或类似转录因子和药学上可接受的组合物的步骤 载体
-
7.发明授权Polypeptide having angiogenesis-inducing activity and antibacterial activity, and use thereof for medical purposes 有权具有血管生成诱导活性和抗菌活性的多肽及其用于医疗目的的用途公开(公告)号：US09376470B2
公开(公告)日：2016-06-28
申请号：US13131796
申请日：2009-11-27
申请人： Takefumi Gemba , Hideki Tomioka , Ryoko Sata , Nao Tamura , Akito Maeda , Toshihide Kanamori , Yoshimi Saito , Shintaro Komaba , Ryuichi Morishita
发明人： Takefumi Gemba , Hideki Tomioka , Ryoko Sata , Nao Tamura , Akito Maeda , Toshihide Kanamori , Yoshimi Saito , Shintaro Komaba , Ryuichi Morishita
IPC分类号： C07K7/04 , C07K14/00 , C07K14/515 , A61K38/00
CPC分类号： C07K14/001 , A61K38/00 , C07K14/515
摘要： Novel polypeptides which have an excellent angiogenesis-inducing activity and an excellent antibacterial activity and medical uses thereof are disclosed. The amino acid sequences of the novel polypeptides are shown in any one of SEQ ID NOs:1 to 6. These polypeptides have angiogenesis-inducing and antibacterial activities. Such polypeptides are useful for the prevention, amelioration or treatment of skin wounds caused by a cut wound, surgical wound, erosion, burn, decubitus, intractable wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease or arteriosclerosis obliteran, and for the prevention, amelioration or treatment of bacterial infection in such skin wounds, and the like.
摘要翻译： 公开了具有优异的血管发生诱导活性和优异的抗菌活性的新型多肽及其医疗用途。 新型多肽的氨基酸序列显示在SEQ ID NO：1至6中的任一个中。这些多肽具有血管发生诱导和抗菌活性。 这样的多肽可用于预防，改善或治疗由切口伤口，手术伤口，侵蚀，烧伤，褥疮，难治性伤口，皮肤溃疡，腿部溃疡，糖尿病性溃疡，闭塞性动脉疾病或闭塞性动脉硬化引起的皮肤伤口，以及 预防，改善或治疗这些皮肤伤口中的细菌感染等。
-
8.发明授权公开(公告)号：US08067388B2
公开(公告)日：2011-11-29
申请号：US12349824
申请日：2009-01-07
CPC分类号： A61K9/127 , A61K31/711 , A61K38/08 , A61K38/1709 , A61K47/10 , A61K47/38 , A61K48/00 , A61K48/0008 , A61K48/005 , C12N15/113 , C12N15/86 , C12N2310/13 , C12N2710/10343 , C12N2740/13043
摘要： A pharmaceutical composition is provided for treatment and prevention of a disease caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. The pharmaceutically acceptable carrier may be a hydrophilic polymer.
摘要翻译： 提供药物组合物用于治疗和预防由NF-κB或ets控制的基因的表达引起的疾病。 组合物包含至少一种诱饵和药学上可接受的载体。 诱饵是NF-＆kgr; B诱饵，ets诱饵，或NF-＆kgr; B和ets的嵌合体诱饵。 该疾病是脑动脉瘤，癌症，马凡氏综合征，主动脉分离，血管成形术后再狭窄，慢性关节风湿病，哮喘，特应性皮炎，肾炎，肾衰竭或斑块破裂。 药学上可接受的载体可以是亲水性聚合物。
-
公开(公告)号：US20110045061A1
公开(公告)日：2011-02-24
申请号：US12938128
申请日：2010-11-02
申请人： Ryuichi Morishita , Toshio Ogihara
发明人： Ryuichi Morishita , Toshio Ogihara
CPC分类号： A61K38/1833 , A61K9/127 , A61K9/1272 , A61K48/00 , A61K48/0016 , A61K48/0025 , A61K48/0075 , C07K14/4753 , C12N7/00 , C12N2760/18843
摘要： It is possible to stimulate the angiogenesis of an ischemic site declined by diabetes and to recuperate ischemic disease by administering HGF (hepatocyte growth factor) gene to the diabetic ischemic.
摘要翻译： 可以通过将糖尿病性缺血性HGF（肝细胞生长因子）基因给予，从而刺激缺血部位的血管发生，并通过糖尿病降低并恢复缺血性疾病。
-
公开(公告)号：US20100240735A1
公开(公告)日：2010-09-23
申请号：US12435335
申请日：2009-05-04
申请人： Ryuichi Morishita , Hiromi Koike , Tadashi Tanabe , Motokuni Aoki
发明人： Ryuichi Morishita , Hiromi Koike , Tadashi Tanabe , Motokuni Aoki
IPC分类号： A61K31/7088 , A61P9/10
CPC分类号： A61K38/52 , A61K31/5585 , A61K31/711 , A61K38/1709 , A61K38/1833 , A61K38/1858 , A61K48/00 , A61K2300/00
摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets 1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.
摘要翻译： 本发明提供：（1）血管生成治疗用药物组合物，其含有选自具有血管扩张作用和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分，以及生成它们的物质; 和编码血管生成因子的基因; （2）增强编码血管生成因子的基因的血管生成作用的药剂，其含有选自具有血管舒张作用和/或血小板聚集抑制作用的物质和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分; （3）含有前列环素合酶基因作为活性成分的血管生成剂; （4）含有ets-1基因和编码血管生成因子的另一基因作为活性成分的用于血管生成治疗的药物组合物; （4）含有ets1基因作为增强编码血管生成因子的另一基因的血管生成作用的活性成分的药剂; 和（5）含有ets-1基因作为活性成分的血管生成剂。
-
-
-
-
-
-
-
-
-
搜索结果
71 条记录 (耗时 0.026 秒)
